Celecoxib inhibits thrombin-induced chondrocyte degeneration in rats

doi:10.12307/2024.834

Abstract

Abstract: BACKGROUND: The content of serum thrombin in patients with osteoarthritis is significantly higher than that in normal individuals, and thrombin can induce inflammatory degeneration of rat chondrocytes, suggesting that inhibiting the function of thrombin may become a method for treating osteoarthritis. Celecoxib is a common therapeutic drug for the clinical treatment of osteoarthritis. It is not yet known whether it improves chondrocyte degeneration by inhibiting the activity of thrombin.
OBJECTIVE: To investigate the effect of celecoxib on thrombin-induced degeneration of rat chondrocytes.
METHODS: Thrombin levels in the serum of osteoarthritis patients and normal individuals were detected by an ELISA kit. Primary chondrocytes of neonatal Sprague-Dawley rats were isolated, and all experiments were performed with cells from passage one. Chondrocytes were randomly divided into three groups: control group, thrombin group, and celecoxib group. The cell morphology of the three groups was observed under an inverted microscope, and an Edu kit was used to detect the cell proliferation. qRT-PCR was used to detect the expression of extracellular matrix components (aggrecan, elastin, cartilage oligomeric matrix proteins), inflammatory factors (interleukin-1, interleukin-6, and tumor necrosis factor-α), and chemokines (monocyte chemotactic protein 2, monocyte chemotactic protein 7, granulocyte chemotactic protein 6). The expression of type 2 collagen α1 was detected by immunofluorescence. Western blot method was used to detect the expression of catabolic metabolism genes, such as matrix metalloproteinase 9, matrix metalloproteinase 13, and cyclooxygenase 2.
RESULTS AND CONCLUSION: Patients with osteoarthritis had higher levels of thrombin in the serum compared with normal individuals. Under the microscope, celecoxib was found to significantly inhibit fibroid changes in chondrocytes. Compared with the thrombin group, celecoxib inhibited the proliferation of chondrocytes. The downregulation of extracellular matrix gene expression, such as type II collagen α1, in the thrombin group was inhibited by celecoxib (P < 0.05). Thrombin promoted the expression of inflammatory factors (interleukin-1, interleukin-6, and tumor necrosis factor-α), chemokines (monocyte chemotactic protein 2, monocyte chemotactic protein 7, granulocyte chemotactic protein 6), as well as catabolic genes (matrix metalloproteinase 9, matrix metalloproteinase 13, and cyclooxygenase 2), and under the intervention of celecoxib, the expression of these genes could be downregulated (P < 0.05). Overall, these findings indicate that celecoxib inhibits the pro-inflammatory effects of thrombin and thereby ameliorates chondrocyte degeneration in rats.

Key words: chondrocyte, thrombin, celecoxib, cell proliferation, cell degeneration

CLC Number:

Zhu Zhiheng, Ding Jiaying, Ge Yangshuo, Huang Chunmeng, Shen Jun, Wang Xuezong, Zheng Yuxin, Ding Daofang. Celecoxib inhibits thrombin-induced chondrocyte degeneration in rats[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(34): 5446-5451.

Figures/Tables 6

References

[1] MANDL LA. Osteoarthritis year in review 2018: clinical. Osteoarthritis Cartilage. 2019;27(3):359-364.
[2] YAO Q, WU X, TAO C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):56.
[3] MAEHARA M, TOYODA E, TAKAHASHI T, et al. Potential of Exosomes for Diagnosis and Treatment of Joint Disease: Towards a Point-of-Care Therapy for Osteoarthritis of the Knee. Int J Mol Sci. 2021;22(5):2666.
[4] SHARMA L. Osteoarthritis of the Knee. N Engl J Med. 2021;384(1): 51-59.
[5] KOHLI P, STEG PG, CANNON CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014;127(1):53-60.
[6] SCHJERNING OLSEN AM, GISLASON GH, MCGETTIGAN P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805-814.
[7] ZHANG X, SHI Y, ZHANG Z, et al. Intra-articular delivery of tetramethylpyrazine microspheres with enhanced articular cavity retention for treating osteoarthritis. Asian J Pharm Sci. 2018;13(3): 229-238.
[8] LIDDLE A D, JUDGE A, PANDIT H, et al. Adverse outcomes after total and unicompartmental knee replacement in 101,330 matched patients: a study of data from the National Joint Registry for England and Wales. Lancet. 2014;384(9952):1437-1445.
[9] YANG Y, ZHANG M, KANG X, et al. Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice. Behav Brain Funct. 2015;11(1):30.
[10] YE X, ZUO D, YU L, et al. ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia. Biochem Biophys Res Commun. 2017;485(2):499-505.
[11] SCHAFFNER A, RHYN P, SCHOEDON G, et al. Regulated expression of platelet factor 4 in human monocytes--role of PARs as a quantitatively important monocyte activation pathway. J Leukoc Biol. 2005;78(1): 202-209.
[12] SOKOLOVA E, GRISHINA Z, BüHLING F, et al. Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L793-L802.
[13] PULJAK L, MARIN A, VRDOLJAK D, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017;5(5):Cd009865.
[14] KRASSELT M, BAERWALD C. Celecoxib for the treatment of musculoskeletal arthritis. Expert Opin Pharmacother. 2019;20(14): 1689-1702.
[15] RIM YA, NAM Y, JU JH. The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression. Int J Mol Sci. 2020;21(7):2358.
[16] VERSTEEG HH, HEEMSKERK JW, LEVI M, et al. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327-358.
[17] ROCHA AL, BIGHETTI-TREVISAN RL, DUFFLES LF, et al. Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts. Thromb Res. 2020;186:45-53.
[18] JABERI N, SOLEIMANI A, PASHIRZAD M, et al. Role of thrombin in the pathogenesis of atherosclerosis. J Cell Biochem Suppl. 2019;120(4): 4757-4765.
[19] BROWN C, BRANDT W, WANG TF, et al. Incidence of recurrent venous thromboembolism and bleeding complications in patients with cancer and isolated distal deep vein thrombosis. Thromb Res. 2023;228:81-84.
[20] PRAKASH S, VERGHESE S, ROXBY D, et al. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care. 2015;30(2):264-270.
[21] KUBO N, AWADA T, HIROSE N, et al. Longitudinal effects of estrogen on mandibular growth and changes in cartilage during the growth period in rats. Dev Biol. 2022;492:126-132.
[22] NI Z, KUANG L, CHEN H, et al. The exosome-like vesicles from osteoarthritic chondrocytes enhanced mature IL-1β production of macrophages and aggravated synovitis in osteoarthritis. Cell Death Dis. 2019;10(7):522.
[23] SALINAS D, MUMEY BM, JUNE RK. Physiological dynamic compression regulates central energy metabolism in primary human chondrocytes. Biomech Model Mechanobiol. 2019;18(1):69-77.
[24] HOSSEINZADEH A, KAMRAVA SK, JOGHATAEI MT, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61(4):411-425.
[25] NA HS, PARK JS, CHO KH, et al. Interleukin-1-Interleukin-17 Signaling Axis Induces Cartilage Destruction and Promotes Experimental Osteoarthritis. Front Immunol. 2020;11:730.
[26] WANG T, HE C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50.
[27] HU Q, ECKER M. Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis. Int J Mol Sci. 2021;22(4):1742.
[28] LI L, JIANG BE. Serum and synovial fluid chemokine ligand 2/monocyte chemoattractant protein 1 concentrations correlate with symptomatic severity in patients with knee osteoarthritis. Ann Clin Biochem. 2015; 52(Pt 2):276-282.
[29] GOODE AP, SCHWARTZ TA, KRAUS VB, et al. Inflammatory, Structural, and Pain Biochemical Biomarkers May Reflect Radiographic Disc Space Narrowing: The Johnston County Osteoarthritis Project. J Orthop Res. 2020;38(5):1027-1037.
[30] SHEN J, ABU-AMER Y, O’KEEFE RJ, et al. Inflammation and epigenetic regulation in osteoarthritis. Connect Tissue Res. 2017;58(1):49-63.
[31] JIANG W, JIN Y, ZHANG S, et al. PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis. Bone Res. 2022;10(1):27.
[32] WIEGERTJES R, VAN DE LOO FAJ, BLANEY DAVIDSON EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford). 2020; 59(10):2681-2694.
[33] VERRICO CD, WESSON S, KONDURI V, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020;161(9):2191-2202.
[34] CHELESCHI S, TENTI S, GIANNOTTI S, et al. A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes. Int J Mol Sci. 2021;22(16):8980.
[35] HAARTMANS MJJ, TIMUR UT, EMANUEL KS, et al. Evaluation of the Anti-Inflammatory and Chondroprotective Effect of Celecoxib on Cartilage Ex Vivo and in a Rat Osteoarthritis Model. Cartilage. 2022; 13(3):19476035221115541.